In 2020, tazemetostat, an EZH2 inhibitor, was approved for the treatment of epithelioid sarcoma, making it the first approved histone “writer” inhibitor and the first used to treat solid tumors167. This evidence concerns the gene EZH2 and epithelioid sarcoma.